このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Kiniksa Pharmaceuticals International マネジメント
マネジメント 基準チェック /44
Kiniksa Pharmaceuticals International'sの CEO はSanj Patelで、 Jul2015年に任命され、 の在任期間は 9.08年です。 の年間総報酬は$ 5.30Mで、 16.3%給与と83.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.38%を直接所有しており、その価値は$ 45.19M 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と7.7年です。
主要情報
Sanj Patel
最高経営責任者
US$5.3m
報酬総額
| CEO給与比率 | 16.3% |
| CEO在任期間 | 9.3yrs |
| CEOの所有権 | 2.4% |
| 経営陣の平均在職期間 | 3.8yrs |
| 取締役会の平均在任期間 | 7.8yrs |
経営陣の近況
Recent updates
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 07
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Jul 24Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$5m | US$864k | US$14m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | US$231m |
| Mar 31 2023 | n/a | n/a | US$196m |
| Dec 31 2022 | US$6m | US$835k | US$183m |
| Sep 30 2022 | n/a | n/a | US$143m |
| Jun 30 2022 | n/a | n/a | -US$112m |
| Mar 31 2022 | n/a | n/a | -US$134m |
| Dec 31 2021 | US$7m | US$803k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$175m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$184m |
| Dec 31 2020 | US$5m | US$780k | -US$161m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$123m |
| Mar 31 2020 | n/a | n/a | -US$122m |
| Dec 31 2019 | US$5m | US$780k | -US$162m |
| Sep 30 2019 | n/a | n/a | -US$173m |
| Jun 30 2019 | n/a | n/a | -US$170m |
| Mar 31 2019 | n/a | n/a | -US$153m |
| Dec 31 2018 | US$7m | US$740k | -US$103m |
| Sep 30 2018 | n/a | n/a | -US$93m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$1m | US$700k | -US$65m |
報酬と市場: Sanjの 総報酬 ($USD 5.30M ) は、 US市場 ($USD 5.67M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Sanjの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Sanj Patel (55 yo)
9.3yrs
在職期間
US$5,297,067
報酬
Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since July 2015. Before founding Kiniksa Pharmaceutica...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.3yrs | US$5.30m | 2.41% $ 43.7m | |
| Senior VP & COO | 2.8yrs | US$1.75m | 0.16% $ 3.0m | |
| Senior VP & Chief Medical Officer | 8.2yrs | US$1.79m | 0.073% $ 1.3m | |
| Senior VP & CFO | 3.8yrs | データなし | 0.032% $ 584.7k | |
| Chief Accounting Officer & Group VP of Finance | 4.7yrs | データなし | 0.037% $ 673.4k | |
| Senior Vice President of Technical Operations | 3.8yrs | データなし | データなし | |
| Senior VP & Chief Compliance Officer | 3.5yrs | データなし | データなし | |
| SVP, General Counsel & Secretary | 3.8yrs | データなし | データなし | |
| Executive Vice President of Corporate Affairs | no data | データなし | データなし | |
| Senior Vice President of Regulatory Affairs | 3.8yrs | データなし | データなし | |
| Senior VP & Chief Commercial Officer | 2.8yrs | データなし | 0.031% $ 553.6k | |
| Chief Business Officer | less than a year | データなし | データなし |
3.8yrs
平均在職期間
51.5yo
平均年齢
経験豊富な経営陣: KNSAの経営陣は 経験豊富 であると考えられます ( 3.5年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.3yrs | US$5.30m | 2.41% $ 43.7m | |
| Independent Director | 6.7yrs | US$362.66k | 0.013% $ 238.8k | |
| Lead Independent Director | 9yrs | US$411.06k | 0.028% $ 505.4k | |
| Independent Director | 7.8yrs | US$380.36k | 0.013% $ 238.8k | |
| Independent Director | 9yrs | US$372.55k | 0.013% $ 238.8k | |
| Independent Director | 5.6yrs | US$459.75k | 0.018% $ 328.4k | |
| Independent Director | 4.3yrs | US$365.36k | 0.013% $ 238.8k | |
| Independent Director | 9yrs | US$371.96k | 0.0070% $ 127.4k | |
| Chairman of Scientific Advisory Board | no data | データなし | 2.08% $ 37.7m | |
| Independent Director | 6.7yrs | US$365.36k | 0.013% $ 238.8k |
7.8yrs
平均在職期間
56yo
平均年齢
経験豊富なボード: KNSAの 取締役会 は 経験豊富 であると考えられます ( 7.5年の平均在任期間)。